You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

Investigational Drug Information for Narlaprevir


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Narlaprevir?

Narlaprevir is an investigational drug.

There have been 7 clinical trials for Narlaprevir. The most recent clinical trial was a Phase 3 trial, which was initiated on May 7th 2014.

The most common disease conditions in clinical trials are Hepatitis, Hepatitis C, Chronic, and Hepatitis C. The leading clinical trial sponsors are R-Pharm, Almedis, and Merck Sharp & Dohme Corp.

Recent Clinical Trials for Narlaprevir
TitleSponsorPhase
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1AlmedisPhase 2
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1ChromSystemsLabPhase 2
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1Scientific Center EFiSPhase 2

See all Narlaprevir clinical trials

Clinical Trial Summary for Narlaprevir

Top disease conditions for Narlaprevir
Top clinical trial sponsors for Narlaprevir

See all Narlaprevir clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.